NeoPhore works with world’s oldest private cancer centre
Cambridge life science company NeoPhore has entered into a three-year research collaboration with Memorial Sloan Kettering Cancer Center (MSK) in New York.
NeoPhore is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system.
The objective of the US alliance is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance tumour immunogenicity and induce tumour immunity.
Building on seminal discoveries and ongoing research of its scientific founders and collaborators, NeoPhore is building a pipeline targeting novel proteins across the DNA mismatch repair pathway.
The company’s first-in-class MMR modulators alter the genotype of tumour cells to elicit increased tumour mutational burden, together with higher neoantigen presentation and immunogenicity which aim to reawaken the anti-tumour immune response and leverage sensitivity to immune checkpoint blockade.
NeoPhore CEO Dr Matthew Baker said: “Collaborating with such prominent leaders in the field of applied cancer genetics is a great privilege.
“NeoPhore's therapeutic concept aims to induce neoantigen creation and cancer immunity using small-molecule inhibitors of mismatch repair, particularly in combination with other immunotherapy approaches.
“We look forward to the outcome of this collaboration which will ultimately advance our goal to develop next-generation immuno-oncology therapeutics.”
NeoPhore was spun-out of the University of Turin and PhoreMost Ltd – also growing from Cambridge – by the CRT Pioneer Fund.
Memorial Sloan Kettering Cancer Center was founded in 1884 and is the world’s oldest and largest private cancer centre. Its team of world-renowned doctors, specialists and scientists deliver what is regarded as sector-leading personalised treatment for patients.